scholarly journals Lymphocyte Rich Hodgkin's Lymphoma Presented with Warm Hemolytic Anemia: A Case Report and Literature Review

2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Jorge M. Hurtado-Cordovi ◽  
Vaibhav Verma ◽  
Vladimir Gotlieb ◽  
Marianne Frieri
Keyword(s):  
Hemolytic Anemia ◽  
Hodgkin’S Lymphoma ◽  
The United States ◽  
Lymph Node Biopsy ◽  
Hodgkin's Lymphoma ◽  
Mediastinal Lymphadenopathy ◽  
Low Grade ◽  
Presenting Symptoms ◽  
Night Sweats ◽  
Pelvic Ct Scan

Hodgkin's lymphoma accounts for ten percent of all lymphomas. In the United States, there are about 8000 new cases every year. This paper describes a case of lymphocyte-rich Hodgkin's lymphoma (LRHL) manifested by autoimmune hemolytic anemia (AIHA). A 27-year-old Israeli male presented with dizziness associated with one month of low-grade fevers and night sweats; he also complained of persistent cough, pruritus, and ten-pound weight lost during this time. The CBC revealed hemoglobin of 5.9 gm/dL, and direct Coomb's test detected multiple nonspecific antibodies consistent with the diagnosis of AIHA. Chest, abdomen, and pelvic CT scan showed mediastinal lymphadenopathy and splenomegaly. Lymph node biopsy revealed classic LRHL. AIHA resolved after completion of the first cycle of chemotherapy with adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD); after six cycles, he went into complete remission. Although infrequent, AIHA can be responsible for the presenting symptoms of HL.

scholarly journals Sarcoid Reactions after Chemotherapy for Hodgkin's Lymphoma

2010 ◽  
Vol 3 ◽  
pp. CCRep.S5243 ◽  
Author(s):  
Baldeep Wirk
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Lymph Node Biopsy ◽  
Hodgkin's Lymphoma ◽  
Mediastinal Lymphadenopathy ◽  
Axillary Lymph ◽  
Chemotherapy Treatment ◽  
Node Biopsy ◽  
Inappropriate Treatment ◽  
Caucasian Female ◽  
New Onset

Introduction There is a reported association between sarcoidosis and malignancy. This is particularly true for lymphomas and is known as the sarcoidosis-lymphoma syndrome. Case report A 49 year old Caucasian female presented with mediastinal and axillary lymphadenopathy. An excisional axillary lymph node biopsy showed classical Hodgkin's lymphoma, nodular sclerosis subtype. She received six cycles of conventional chemotherapy achieving a complete remission with no evidence of any lymphadenopathy on restaging imaging. However, one month after completion of chemotherapy, she developed new onset of progressive mediastinal lymphadenopathy. A mediastinoscopy and biopsy was performed showing noncaseating granulomata and the patient was diagnosed with a sarcoid reaction. Conclusion Sarcoidosis and sarcoid reactions must be considered in the differential diagnosis when assessing patients with persistent or enlargening masses after chemotherapy treatment for Hodgkin's lymphoma, especially since this is associated with a better prognosis. A tissue biopsy is essential prior to starting chemotherapy for presumed relapsed malignancy or persistent disease so as to avoid inappropriate treatment.

scholarly journals Fludarabine: An active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin's lymphoma

1993 ◽  
Vol 4 (7) ◽  
pp. 575-578 ◽  
Author(s):  
P.L. Zinzani ◽  
F. Lauria ◽  
D. Rondelli ◽  
D. Benfenati ◽  
D. Raspadori ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Active Agent ◽  
Hodgkin's Lymphoma ◽  
Low Grade ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Previously Treated

Concomitant Primary Low Grade Non-Hodgkin's Lymphoma of the Spleen and Breast Carcinoma

1992 ◽  
Vol 7 (4) ◽  
pp. 337-339 ◽  
Author(s):  
Rudole Weide ◽  
Christian Görg ◽  
Karl-Heinz Pflüger ◽  
Annette Ramaswamy ◽  
Armin Steinmetz ◽  
...  
Keyword(s):  
Breast Carcinoma ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Low Grade ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

Coherent view of non-Hodgkin's lymphoma.

1995 ◽  
Vol 13 (10) ◽  
pp. 2656-2675 ◽  
Author(s):  
A C Aisenberg
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Large Cell ◽  
Hodgkin's Lymphoma ◽  
Malignant Neoplasms ◽  
Low Grade ◽  
Cell Leukemia Virus Type ◽  
Microscopic Appearance ◽  
Non Hodgkin’S Lymphoma ◽  
Incidence And Mortality ◽  
Non Hodgkin's Lymphoma

PURPOSE Even though non-Hodgkin's lymphoma is already sixth in incidence and mortality among malignant neoplasms (and the incidence was increasing at a rate of 3% to 4% per year before the advent of AIDS epidemic-associated lymphomas), most physicians and many oncologists find the disorder arcane. The problem lies in the complexity of human lymphoma, which encompasses more than a dozen neoplasms of the lymphoid system. The goal of this review is to provide user-friendly access to the condition. METHODS The variety of inputs required for a subdivision of non-Hodgkin's lymphoma that is useful to clinicians includes lymphocyte lineage and sublineage based on microscopic appearance and immunophenotype, clinical behavior manifest in survival and early dissemination, and analysis of molecular genetic and cytogenetic abnormalities, which reflect pathogenic oncogene derangements. Epstein-Barr virus (EBV) and human T-cell leukemia virus type 1 (HTLV-1) are important in certain uncommon lymphomas. RESULTS AND CONCLUSION The subtypes of primary B-lineage nodal lymphoma include low-grade (small lymphocytic, lymphoplasmacytic-lymphoplasmacytoid, follicular small cleaved cell, and follicular mixed small cleaved and large cell), intermediate-grade (follicular large cell, diffuse small cleaved or mixed, and intermediate lymphocytic), and high-grade (diffuse large cell, immunoblastic, and small noncleaved cell) neoplasms. The less common lymphomas of T lineage and lymphomas that arise in extranodal sites are placed in separate subdivisions. This subdivision serves as a guide to prognosis and treatment.

scholarly journals Translocation (14;18)-positive cells are present in the circulation of the majority of patients with localized (stage I and II) follicular non- Hodgkin's lymphoma

Blood ◽  
1993 ◽  
Vol 82 (8) ◽  
pp. 2510-2516 ◽  
Author(s):  
AC Lambrechts ◽  
PE Hupkes ◽  
LC Dorssers ◽  
MB van't Veer
Keyword(s):  
Bone Marrow ◽  
Lymph Node ◽  
Peripheral Blood ◽  
Hodgkin’S Lymphoma ◽  
Lymph Node Biopsy ◽  
Stage I ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Sensitive Polymerase Chain Reaction

Abstract Stage I and II follicular non-Hodgkin's lymphoma (NHL) is clinically defined as a localized disease. To study the possibility that this disease is in fact disseminated, we used the sensitive polymerase chain reaction (PCR) method using translocation (14;18) as marker. Samples from 21 patients who were clinically diagnosed with stage I or II follicular NHL were analyzed for the presence of t(14;18)-positive cells using PCR. We analyzed (1) the diagnostic lymph node biopsy and (2) the peripheral blood or bone marrow samples from these patients. Translocation (14;18) cells were detected in the diagnostic lymph node biopsies of 12 patients. In 9 of these patients, t(14;18)-positive cells were detected in peripheral blood and/or bone marrow samples at diagnosis and/or after therapy. Thus, in 75% of the follicular NHL patients carrying the t(14;18) as a marker for lymphoma cells, t(14;18)- positive cells were detected in peripheral blood and bone marrow at diagnosis and after therapy. Our results show that t(14;18)-positive cells can be detected in the circulation of patients with stage I and II follicular NHL, indicating that, although diagnosed as localized, the disease is disseminated.

Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment

2000 ◽  
Vol 18 (17) ◽  
pp. 3135-3143 ◽  
Author(s):  
Thomas A. Davis ◽  
Antonio J. Grillo-López ◽  
Christine A. White ◽  
Peter McLaughlin ◽  
Myron S. Czuczman ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Phase Iii ◽  
Low Grade ◽  
Phase Iii Trial ◽  
Safety And Efficacy ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Anti Cd20

PURPOSE: This phase II trial investigated the safety and efficacy of re-treatment with rituximab, a chimeric anti-CD20 monoclonal antibody, in patients with low-grade or follicular non-Hodgkin’s lymphoma who relapsed after a response to rituximab therapy. PATIENTS AND METHODS: Fifty-eight patients were enrolled onto this study, and two were re-treated within the study. Patients received an intravenous infusion of 375 mg/m2 of rituximab weekly for 4 weeks. All patients had at least two prior therapies and had received at least one prior course of rituximab, with a median interval of 14.5 months between rituximab courses. RESULTS: Most adverse experiences (AEs) were transient grade 1 or 2 events occurring during the treatment period. Clinically significant myelosuppression was not observed; hematologic toxicity was generally mild and reversible. No patient developed human antichimeric antibodies after treatment. The type, frequency, and severity of AEs in this study were not apparently different from those reported in the phase III trial of rituximab. The overall response rate in 57 assessable patients was 40% (11% complete response and 30% partial responses). Median time to progression (TTP) in responders and median duration of response (DR) have not been reached, but Kaplan-Meier estimated medians are 17.8 months (range, 5.4+ to 26.6 months) and 16.3 months (range, 3.7+ to 25.1 months), respectively. These estimated medians are longer than the medians achieved in the patients’ prior course of rituximab (TTP and DR of 12.4 and 9.8 months, respectively, P > .1) and in a previously reported phase III trial (TTP in responders and DR of 13.2 and 11.6 months, respectively). Responses are ongoing in seven of 23 responders. CONCLUSION: In this re-treatment population, safety and efficacy were not apparently different from those after initial rituximab exposure.

Sign in / Sign up

Export Citation Format

Share Document